Cipla Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Cipla Ltd. authored by Deven Choksey and published by - Trendlyne research reports.
Item: Cipla Ltd.
Rating: 3
Author: Deven Choksey

Keep track of all breaking news and updates on Cipla Ltd. from all sources in a single place.

Load latest

Cipla Ltd.

10 Sep 2025

1532.10

0.41%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herein mention the schedule of Analyst / Institutional Investor Meeting with the Company.

pdf

Cipla Ltd.

08 Sep 2025

1532.10

0.41%

Growth outlook intact despite near-term headwinds

Hold: Cipla Ltd.

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by +0.9%/-5.2%, as we factor in lower revenue on account of ramp down of Revlimid portfolio and ongoing price erosion in the US market, higher depreciation and amortization expense, offset by higher other income.

Cipla Ltd. is trading above its 200 day SMA of 1505.7

Cipla Ltd.

05 Sep 2025

1532.10

0.41%

Cipla launches Huena, India's first non-antibiotic drug to fight UTI

Business Standard

Drug firm Cipla on Friday said it has introduced a non-antibiotic treatment for patients suffering from recurrent urinary tract infections. The company has launched Methenamine Hippurate under the brand name HUENA. This marks a significant step forward for the company in its fight against anti-microbial resistance as it becomes the first to introduce such treatment in India, the Mumbai-based drugmaker said in a statement. Urinary tract infections (UTIs) are the second most common reason for antibiotic use in India, with infection cases doubling over the last 30 years. Women are more susceptible to UTIs, which account for 15 per cent of overall antibiotic prescriptions. Methenamine Hippurate offers an effective, non-antibiotic alternative for preventing UTIs by targeting bacteria in the bladder and urinary tract. Studies show it is as effective as long-term, low-dose antibiotic therapy for UTI prevention, with lower costs and no risk of antibiotic resistance. "We believe this...

Cipla Ltd. is trading above its 200 day SMA of 1505.7

Cipla Ltd.

02 Sep 2025

1532.10

0.41%

India, RoW biz to stay steady, US drug pipeline - the next trigger

Buy: Cipla Ltd.

Target

Sharekhan

Cipla has robust domestic and global product pipelines. US product pipeline to be healthy and will be key to driving growth from H2FY26E and contribute significantly from FY27E onwards.

Cipla Ltd. is trading below its 30 day SMA of 1545.1

Cipla Ltd.

27 Aug 2025

1532.10

0.41%

Cipla Recalls Over 20,000 Packs Of Inhalation Drug In US

NDTV Profit

The company is recalling 20,352 packs of the inhalation drug due to 'Failed Stability Specifications

Cipla Ltd. is trading above its 200 day SMA of 1505.7

Cipla recalls over 20k packs of inhalation drug in US

Business Line | 27 Aug 2025

Cipla Ltd.

26 Aug 2025

1532.10

0.41%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Updates on Acquisition

BSE India

Update on acquisition of securities in iCaltech Innovations Private Limited.

pdf

Cipla Ltd.

22 Aug 2025

1532.10

0.41%

Five Stocks To Buy Today: Devyani, Cipla, IndusInd Bank And OthersCheck Target Price

NDTV Profit

The stock recommendations come with specific target price and stop loss price.

Number of FII/FPI investors decreased from 1124 to 1085 in Sep 2025 qtr

Cipla Ltd.

22 Aug 2025

1532.10

0.41%

Looking for short-term F&O trade? Check this 'Bull Spread' on Cipla

Business Standard

Short term trend is positive as it is placed above its 5, 11 and 20 day EMA Stock price has broken out on the weekly chart with higher volumes

Cipla Ltd. has an average target of 1703.00 from 9 brokers.

Cipla Ltd.

19 Aug 2025

1532.10

0.41%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper publication regarding 100 days campaign - "Saksham Niveshak"

pdf

Cipla Ltd.

13 Aug 2025, 06:31PM

1532.10

0.41%

Company Update

Cipla Ltd - 500087 - Intimation Of Cancellation Of Schedule Of Analyst / Institutional Investor Meetings

BSE India

In furtherance to our intimation dated 30th June, 2025 and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that the Company has decided not to participate in the JP Morgan Conference scheduled on 23rd September, 2025.

pdf